22nd Century Group, Inc (XXII) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in 22nd Century Group (XXII) by buying shares or fractional shares at any major US broker, or as one small holding in a speculative or thematic basket. 22nd Century is a small tobacco and plant-science company whose central asset is VLN, the only combustible cigarette the FDA has authorized to be marketed as reduced-nicotine, alongside contract-manufacturing and hemp/cannabis plant-biotech interests. The single most important thing to understand is that this is a deeply speculative, distressed micro-cap: it has run ongoing operating losses, raised money repeatedly, and executed a series of large reverse stock splits to stay listed on Nasdaq, so the story is a high-risk turnaround bet, not a stable business.
XXII stock price
As of 2026-07-14, 22nd Century Group, Inc (XXII) last closed at $4.19, down 99.7% over the past year. Over the past 52 weeks it has traded between $3.90 and $1,542.00.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or 22nd Century Group, Inc's investor relations page. Walnut is informational, not investment advice.
What does 22nd Century Group, Inc (XXII) do?
22nd Century Group Inc. is a tobacco and plant-biotechnology company best known for VLN, its reduced-nicotine-content combustible cigarette, which is the only such product the FDA has authorized to be marketed with reduced-nicotine claims. The company has been commercializing VLN through retail trials in a growing number of US states (including a 2026 expansion into California under the Pinnacle VLN brand) and advancing additional PMTA submissions and licensing plans, including a 100mm-length product aimed at a larger share of the US cigarette market. It also runs contract-manufacturing of conventional tobacco products and has interests in hemp/cannabis and other plant-science lines, though tobacco is the core. The bull thesis rests heavily on regulation: a long-discussed FDA proposal to mandate very low nicotine levels in cigarettes would, if enacted, position VLN's technology at the center of the market.
The investment reality, however, is that of a distressed micro-cap. Revenue has been small (on the order of the mid-teens of millions of dollars in 2025) and the company has continued to post gross and operating losses, with going-concern pressure a recurring theme in its history. To fund operations and satisfy Nasdaq's minimum bid-price rule, 22nd Century has repeatedly raised capital through dilutive equity and warrant deals and executed multiple large reverse stock splits in a short span (including a 1-for-135 in December 2024 and further splits in 2025 and 2026). Each split cuts the share count without adding value, and each capital raise dilutes existing holders, which is why the stock has lost the vast majority of its value over time despite the appeal of the VLN asset.
What's driving 22nd Century Group, Inc (XXII)?
1. FDA reduced-nicotine rule as the core catalyst
The single biggest driver of the bull case is regulatory. The FDA has long floated a product standard that would cap nicotine in combustible cigarettes at minimally or non-addictive levels. If such a rule advances, VLN, as the only FDA-authorized reduced-nicotine cigarette, would be positioned at the heart of a reshaped market. This is a genuine, differentiated asset, but it is also a binary bet: the rule has been proposed and stalled before, timing is uncertain, and the outcome is outside the company's control.
2. VLN commercialization and state-by-state expansion
22nd Century has been rolling VLN out through retail trials in a growing list of states, including a 2026 launch into California under the Pinnacle VLN brand, and is pursuing additional PMTA submissions and a longer 100mm product plus licensing arrangements to widen reach. Turning these trials into durable, self-sustaining sales volume is the operational test. So far revenue has stayed small, so investors are being asked to underwrite future adoption rather than current results.
3. Contract manufacturing and plant-science assets
Beyond VLN, the company operates a tobacco contract-manufacturing business and retains plant-biotechnology interests in hemp/cannabis and related lines. These provide some revenue and optionality, but they have not been enough to offset operating losses. The strategic direction has narrowed over time toward the reduced-nicotine tobacco opportunity, so these ancillary lines are supporting cast rather than the main thesis.
4. Balance sheet, dilution, and Nasdaq listing survival
The defining near-term thrust is simply staying solvent and listed. The company has repeatedly raised dilutive equity and warrant capital and executed multiple large reverse stock splits to hold its Nasdaq listing. Any assessment of XXII has to weight how much further dilution is likely and whether cash on hand funds operations to the next milestone. This financial fragility, not the product, is what has driven the stock's performance to date.
What are the risks to 22nd Century Group, Inc (XXII)?
The risks here are severe and central to the story. 22nd Century has a history of operating losses and going-concern warnings, and it has funded itself through repeated dilutive equity and warrant issuance, so existing shareholders have been diluted heavily and could be again. Multiple large reverse stock splits (including 1-for-135 in December 2024 and further splits in 2025 and 2026) have been used to maintain the Nasdaq minimum bid price; reverse splits do not create value and often precede further declines. The core VLN thesis depends on an FDA reduced-nicotine mandate that has been proposed and delayed before and may never take effect, making a large part of the upside binary and outside the company's control. Tobacco regulation, litigation exposure, small revenue, thin trading, and the ever-present possibility of delisting all compound the risk. This is a distressed micro-cap that can lose value quickly and should be sized accordingly.
How is 22nd Century Group, Inc (XXII) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see 22nd Century Group, Inc's investor relations page or your broker.
- Revenue trend: Small (roughly the mid-teens of millions of dollars in 2025); quarterly revenue has been modest, in the low single-digit millions, figures approximate and to be verified live
- Profitability: Unprofitable, with continued gross and operating losses; going-concern pressure has been a recurring theme in the company's history
- Balance sheet: Fragile; the company has relied on repeated dilutive equity and warrant financings to fund operations, so cash runway is a live question, verify the latest filing
- Share structure: Repeatedly reverse-split (including 1-for-135 in Dec 2024 plus further splits in 2025 and 2026) to keep the Nasdaq minimum bid price; share count has been reset several times
- Market cap tier: Nano/micro-cap; a small, highly speculative valuation that can move violently on financing and regulatory news
- Valuation note: With ongoing losses, standard earnings multiples do not apply; the stock trades on the option value of the VLN/reduced-nicotine thesis versus dilution and delisting risk, not on fundamentals
All figures are approximate, tied to the asOf date, and must be verified against the latest SEC filings before acting; reverse splits and financings can change the share count and per-share figures dramatically between filings. Because the company is loss-making, price-to-earnings and similar multiples are not meaningful. What matters is cash runway, the pace of dilution, listing compliance, and whether the FDA reduced-nicotine mandate advances. Treat any headline number here as a starting point for your own research, not a precise metric, and recognize this is among the higher-risk names an investor can hold.
Who competes with 22nd Century Group, Inc (XXII)?
Large tobacco incumbents
Altria, Philip Morris International, and British American Tobacco dominate the cigarette and next-generation nicotine market with enormous scale, distribution, and reduced-risk product portfolios. They dwarf 22nd Century and could develop or license their own reduced-nicotine products if an FDA mandate arrived, making them both the market 22nd Century wants to disrupt and a competitive threat to its head start.
Reduced-risk and nicotine-alternative players
Companies focused on vapor, heated tobacco, oral nicotine pouches, and cessation products, from PMI's IQOS and the pouch category to smaller vapor names, compete for the same smokers 22nd Century targets. Reduced-nicotine cigarettes are one of several approaches to a lower-harm market, and adoption of alternatives could either shrink or reshape the opportunity for VLN.
Speculative small-cap and plant-science peers
As a distressed micro-cap with plant-biotech and hemp/cannabis interests, 22nd Century sits alongside other speculative small-cap names in tobacco alternatives and agricultural biotech that trade on catalysts and financing rather than earnings. For most investors, diversified tobacco or consumer-staples exposure is a far lower-risk way to invest in the nicotine theme than a single distressed name like XXII.
How to invest in 22nd Century Group, Inc (XXII)
There are three common ways to get XXII exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so XXII sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where XXII fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on 22nd Century Group, Inc (XXII)
22nd Century Group owns a genuinely unique asset (FDA-authorized reduced-nicotine VLN cigarettes) whose upside is tied to whether reduced-nicotine tobacco becomes a regulated standard, but the company has burned cash, issued and reverse-split its stock repeatedly, and faces heavy dilution risk. It is a lottery-ticket-style turnaround, appropriate only for money you can afford to lose.
Build a basket around XXII with Walnut
Use 22nd Century Group, Inc as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is XXII a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a genuinely unique asset, VLN, the only FDA-authorized reduced-nicotine cigarette, whose value could jump if the FDA mandates low-nicotine cigarettes. The bear case is that this is a distressed micro-cap with ongoing losses, a history of heavy dilution, and multiple reverse stock splits used to stay listed. It is a high-risk, potentially total-loss speculation, so weigh it carefully and size it accordingly.
What does 22nd Century Group actually do?
+
22nd Century is a tobacco and plant-science company whose flagship product is VLN, a reduced-nicotine-content combustible cigarette that the FDA has authorized to be marketed with reduced-nicotine claims. It commercializes VLN through retail trials, runs a tobacco contract-manufacturing business, and holds hemp/cannabis and other plant-biotech interests. The reduced-nicotine tobacco opportunity is the core of the current strategy.
Why has XXII done so many reverse stock splits?
+
22nd Century has executed multiple large reverse stock splits (including a 1-for-135 in December 2024 and further splits in 2025 and 2026) mainly to keep its share price above Nasdaq's minimum bid-price requirement and avoid delisting. A reverse split combines many shares into fewer, raising the price per share without adding any value. Repeated reverse splits are typically a sign of a distressed stock and have often preceded further declines here.
Is 22nd Century Group at risk of going out of business?
+
The company has a history of operating losses and going-concern pressure, and it has relied on repeated dilutive financings to fund itself, so its survival depends on continued access to capital and progress on VLN. That does not mean failure is certain, but financial fragility and the risk of delisting are real and central to the investment case. Always review the latest filings for current cash runway and going-concern language before acting.
What is VLN and why does it matter?
+
VLN is 22nd Century's reduced-nicotine-content cigarette and is the only combustible cigarette the FDA has authorized to be marketed with reduced-nicotine claims. It matters because the FDA has long discussed requiring cigarettes to contain minimally or non-addictive nicotine levels. If such a rule took effect, VLN's technology could become central to the market, which is the main reason investors follow the stock.
How does the FDA reduced-nicotine rule affect XXII?
+
A proposed FDA product standard would cap nicotine in cigarettes at very low levels. Because VLN is already an FDA-authorized reduced-nicotine cigarette, such a rule could dramatically expand its potential market and is the core of the bull case. However, the proposal has been floated and delayed before, its timing is uncertain, and it may never take effect, so this catalyst is binary and outside the company's control.
Does 22nd Century Group pay a dividend?
+
No. As a loss-making company that has repeatedly raised capital to fund operations, 22nd Century does not pay a dividend, and income is not a reason to own it. Any cash the company holds is needed for operations and commercialization, not distributions. Investors in XXII are betting entirely on a speculative turnaround, not on receiving a payout.
Why is XXII so volatile?
+
XXII is a distressed nano/micro-cap whose price swings on financing announcements, reverse splits, and regulatory headlines rather than steady earnings. Thin trading volume, a small share count that has been reset by repeated reverse splits, and a binary regulatory catalyst all amplify moves. The stock can rise or fall sharply in a single session on news, which is characteristic of speculative, low-priced names.
What are the main risks of investing in XXII?
+
The risks are severe: ongoing operating losses and going-concern history, heavy and likely continued dilution from equity and warrant raises, repeated reverse stock splits used to keep the Nasdaq listing, and a core thesis that hinges on an FDA rule that may never take effect. Tobacco regulation, litigation exposure, thin trading, and delisting risk add more. This is among the higher-risk stocks an investor can hold, with a real possibility of large or total loss.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with 22nd Century Group, Inc's investor relations page or your broker before making investment decisions.